Published in Blood Weekly, October 2nd, 2003
In addition, IsoTis announced further steps to streamline its operations.
IsoTis' management, in its continued effort to rationalize its operations and to fully focus on orthobiologics, intends to discontinue or spin-off all its cell biology programs. This would involve putting on hold the development of VivesCart, a long-term tissue engineered cartilage development program; the transfer of people...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.